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Introduction

Algorithm

• Adenocarcinomas of the lung are the least correlated with
smoking and tend to be found in younger patients.
• Lung cancers unrelated to smoking have different mutational
profiles.
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Companion diagnostics is the use of specific tests whose results
are linked to a particular drug. It allows clinicians the ability to better
target the mechanism of pathology in the patient and follow it up
with a therapy specifically designed to treat the disease process at
hand. This approach to medicine has particularly been championed
in the field of oncology with the development of such drugs as
Zelboraf for the treatment of metastatic melanoma with the
BRAFV600 mutation or Xalkori for late stage lung cancer
expressing an abnormal ALK protein. In the case of non-small cell
lung cancer (NSCLC) Jefferson has developed an algorithm to
establish if patients are positive for mutations of EGFR or
alterations of ALK, ROS1, or RET genes in which case patients can
be treated with drugs such as erlotinib, crizotinib, and cabozantinib.

Mutation Profile for NSCLC
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Figure 2. Biopsy staining positive for the ALK rearrangement and
depiction of FDA approved rearrangement probe used.
Pre-treatment

After 6 weeks of crizotinib
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METHODS

• DNA sequencing is done to establish positive EGFR mutation.
• Fluorescence In Situ Hybridization (FISH) is used to establish
ALK, ROS1, and RET alterations.
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Fig. 1: Stratification of lung cancer patients by mutations and/or
over-expression of various oncogenes.
[Discovery Medicine; ISSN: 1539-6509; eISSN: 1944-7930. Discov Med 10(51):144-150, August 2010.]
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Figure 3. ALK positive NSCLC patient treated at Jefferson
University Hospital with crizotonib.
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